, Volume 64, Issue 18, pp 2091–2097 | Cite as

Brivudin (Bromovinyl Deoxyuridine)

  • Susan J. KeamEmail author
  • Therese M. Chapman
  • David P. Figgitt
Adis Drug Profile


  • ▴ Brivudin is an oral thymidine analogue indicated for the early treatment of acute herpes zoster in immunocompetent adults. It has high, selective activity against varicella zoster virus (VZV), inhibiting VZV replication, possibly through competitive inhibition of viral DNA polymerase, or by acting as an alternative substrate to deoxythymidine triphosphate, causing viral DNA strand breakage.

  • ▴ In a large, 7-day, phase III trial in immunocompetent patients with herpes zoster, once-daily brivudin 125mg was significantly more effective than oral acyclovir 800mg five times daily in reducing the mean time from start of treatment to last vesicular eruption, and was as effective as acyclovir at healing lesions and alleviating acute zoster-related pain.

  • ▴ The likelihood of developing post-herpetic neuralgia (PHN) in immunocompetent patients aged ≥50 years was significantly lower with brivudin than with acyclovir.

  • ▴ Brivudin was as effective as oral famciclovir 250mg three times daily in terms of the prevalence of PHN, the time to last vesicular eruption and lesion healing in another large, 7-day, phase III study in immunocompetent patients with herpes zoster.

  • ▴ Oral brivudin is generally well tolerated, with a similar tolerability profile to those of oral acyclovir or famciclovir. Nausea was the most commonly reported adverse event.


Herpes Zoster Acyclovir Varicella Zoster Virus Immunocompetent Patient Famciclovir 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Johnson RW. Herpes zoster and postherpetic neuralgia: optimal treatment. Drugs Aging 1997 Feb; 10(2): 80–94PubMedCrossRefGoogle Scholar
  2. 2.
    Wutzler P. Antiviral therapy of herpes simplex and varicellazoster virus infections. Intervirology 1997; 40(5–6): 343–56PubMedCrossRefGoogle Scholar
  3. 3.
    Whitley RJ, Shukla S, Crooks RJ. The identification of risk factors associated with persistent pain following herpes zoster. J Infect Dis 1998; 178 Suppl. 1: S71–75PubMedCrossRefGoogle Scholar
  4. 4.
    Wassilew SW, Wutzler P. Oral brivudin in comparison with acyclovir for improved therapy of herpes zoster in immunocompetent patients: results of a randomized, double-blind, multicentered study. On behalf of the Brivudin Herpes Zoster Study Group. Antiviral Res 2003 Jun; 59(1): 49–56PubMedCrossRefGoogle Scholar
  5. 5.
    Shigeta S, Yokota T, De Clercq E. Therapy of varicella-zoster virus infection: mechanism of action of (E)-5-(2-bromovinyl)-2′-deoxyuridine. Antiviral Res 1985; Suppl. 1: 35–44Google Scholar
  6. 6.
    Menarini International Operations Luxembourg S.A., Berlin-Chemie AG. Premovir® 125mg European SmPC. Menarini International Operations Luxembourg S.A. Berlin-Chemie AG, 2004Google Scholar
  7. 7.
    Andrei G, Snoeck R, Reymen D, et al. Comparative activity of selected antiviral compounds against clinical isolates of varicella-zoster virus. Eur J Clin Microbiol Infect Dis 1995 Apr; 14(4): 318–29PubMedCrossRefGoogle Scholar
  8. 8.
    Ono K, Nakane H, De Clercq E. Potent inhibitory effects of the 5′-triphosphates of (E)-5-(2-bromovinyl)-2′-deoxyuridine and (E)-5-(2-bromovinyl)-1-β-D-arabinofuranosyluracil on DNA polymerase γ. Eur J Biochem 1990 Jul 5; 190(3): 463–7PubMedCrossRefGoogle Scholar
  9. 9.
    Lilie HM, Wassilew SW. The role of antivirals in the management of neuropathic pain in the older patient with herpes zoster. Drugs Aging 2003; 20(8): 561–70PubMedCrossRefGoogle Scholar
  10. 10.
    Shigeta S, Yokata T, Iwabuchi T, et al. Comparative efficacy of antiherpes drugs against various strains of varicella-zoster virus. J Infect Dis 1983; 147(3): 576–84PubMedCrossRefGoogle Scholar
  11. 11.
    Baba M, Konno K, Shigeta S, et al. Inhibitory effects of selected antiviral compounds on newly isolated clinical varicella-zoster strains. Tohoku J Exp Med 1986; 148: 275–83PubMedCrossRefGoogle Scholar
  12. 12.
    De Clercq E, Descamps J, Ogata M, et al. In vitro susceptibility of varicella-zoster virus to E-5-(2-bromovinyl)-2′-deoxyuridine and related compounds. Antimicrob Agents Chemother 1982 Jan; 21(1): 33–8PubMedCrossRefGoogle Scholar
  13. 13.
    Rabasseda X. Brivudine: a herpes virostatic with rapid antiviral activity and once-daily dosing. Drugs Today (Barc) 2003 May; 39(5): 359–71CrossRefGoogle Scholar
  14. 14.
    Gross G, Doerr HW. Herpes zoster guidelines of the German Dermatological Society [letter]. J Clin Virol 2003; 27: 308–9PubMedCrossRefGoogle Scholar
  15. 15.
    Keizer HJ, Cleton FJ, de Bruyn EA, et al. Pharmacokinetic and phase-1 studies of oral low dose bromovinyldeoxyuridine (BVdUrd) and 5-fluorouracil (FUra) infusion [abstract no. 132]. Invest New Drugs 1989 Nov; 7(4): 381Google Scholar
  16. 16.
    Wassilew SW, Wutzler P. Oral brivudin in comparison with acyclovir for herpes zoster: a survey study on postherpetic neuralgia. On behalf of the Brivudin Herpes Zoster Study Group. Antiviral Res 2003 Jun; 59(1): 57–60PubMedCrossRefGoogle Scholar
  17. 17.
    Wutzler P, Wassilew S. Brivudin in the treatment of herpes zoster [abstract no. SA 183 plus poster]. 23rd International Congress of Chemotherapy; 2003 Jun 7–9; Durban, 23Google Scholar
  18. 18.
    Wutzler P, De Clercq E, Wutke K, et al. Oral brivudin vs. intravenous acyclovir in the treatment of herpes zoster in immunocompromised patients: a randomized double-blind trial. J Med Virol 1995 Jul; 46(3): 252–7PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2004

Authors and Affiliations

  • Susan J. Keam
    • 1
    Email author
  • Therese M. Chapman
    • 1
  • David P. Figgitt
    • 1
  1. 1.Adis International LimitedMairangi Bay, AucklandNew Zealand

Personalised recommendations